Introducing A Cell Line Mimic To Support Acute Myeloid Leukemia Diagnosis

A large pharmaceutical company facing issues associated with the low expression of key markers on Kasumi-3 cells, reached out for assistance addressing the challenge of an appropriate control for acute myeloid leukemia. Slingshot Biosciences was contacted to develop a synthetic Kasumi-3 AML cell line expressing CD34, CD117, CD45, and CD33 to mimic the AML myeloid lineage at a target Mean Fluorescence Intensity (MFI) of ~105 for all biomarkers.

After a successful partnership, the company determined that the performance of the Slingshot Biosciences synthetic Kasumi-3 cell mimic is similar to a staining control of Kasumi-3 cells.